169 related articles for article (PubMed ID: 29788416)
41. Frequency and characteristics of infusion reactions during biosimilar infliximab treatment in inflammatory bowel diseases: results from Central European nationwide cohort.
Bálint A; Rutka M; Végh Z; Kürti Z; Gecse KB; Banai J; Bene L; Gasztonyi B; Kristóf T; Lakatos L; Miheller P; Palatka K; Patai Á; Salamon Á; Szamosi T; Szepes Z; Tóth GT; Vincze Á; Bor R; Milassin Á; Fábián A; Nagy F; Kolar M; Bortlik M; Duricova D; Hruba V; Lukas M; Mitrova K; Malickova K; Lukas M; Lakatos PL; Molnár T; Farkas K
Expert Opin Drug Saf; 2017 Aug; 16(8):885-890. PubMed ID: 28504555
[TBL] [Abstract][Full Text] [Related]
42. Pediatric rheumatology infusion center: report on therapeutic protocols and infusions given over 4 Years with focus on adverse events over 1 Year.
Vinod SS; Reed AB; Maxwell J; Cron RQ; Stoll ML
Pediatr Rheumatol Online J; 2018 Mar; 16(1):16. PubMed ID: 29523211
[TBL] [Abstract][Full Text] [Related]
43. Human antichimeric antibody in children and young adults with inflammatory bowel disease receiving infliximab.
Miele E; Markowitz JE; Mamula P; Baldassano RN
J Pediatr Gastroenterol Nutr; 2004 May; 38(5):502-8. PubMed ID: 15097438
[TBL] [Abstract][Full Text] [Related]
44. Infliximab reintroduction is not associated to a higher rate of immune-related adverse effects in patients with inflammatory bowel disease initially treated with a three-infusion induction regimen.
Domènech E; Zabana Y; Mañosa M; Garcia-Planella E; Cabré E; Gassull MA
J Clin Gastroenterol; 2010 Jan; 44(1):34-7. PubMed ID: 19417683
[TBL] [Abstract][Full Text] [Related]
45. Impact of rapid infliximab infusions on access at a large academic tertiary medical center.
Pusateri A; Hatcher A; Patel N; Lehman J; Hinton A; Afzali A
Am J Health Syst Pharm; 2021 Nov; 78(22):2046-2052. PubMed ID: 34050749
[TBL] [Abstract][Full Text] [Related]
46. Infliximab for the treatment of psoriasis in the U.K.: 9 years' experience of infusion reactions at a single centre.
Wee JS; Petrof G; Jackson K; Barker JN; Smith CH
Br J Dermatol; 2012 Aug; 167(2):411-6. PubMed ID: 22404545
[TBL] [Abstract][Full Text] [Related]
47. Tolerability of one hour 10 mg/kg infliximab infusions in patients with inflammatory bowel disease.
Babouri A; Buisson A; Bigard MA; Peyrin-Biroulet L
J Crohns Colitis; 2013 Mar; 7(2):129-33. PubMed ID: 22472090
[TBL] [Abstract][Full Text] [Related]
48. Improved Long-term Outcomes of Patients With Inflammatory Bowel Disease Receiving Proactive Compared With Reactive Monitoring of Serum Concentrations of Infliximab.
Papamichael K; Chachu KA; Vajravelu RK; Vaughn BP; Ni J; Osterman MT; Cheifetz AS
Clin Gastroenterol Hepatol; 2017 Oct; 15(10):1580-1588.e3. PubMed ID: 28365486
[TBL] [Abstract][Full Text] [Related]
49. Infliximab therapy in children and adolescents with inflammatory bowel disease.
Veres G; Baldassano RN; Mamula P
Drugs; 2007; 67(12):1703-23. PubMed ID: 17683171
[TBL] [Abstract][Full Text] [Related]
50. Safety of ferric carboxymaltose immediately after infliximab administration, in a single session, in inflammatory bowel disease patients with iron deficiency: a pilot study.
Cortes X; Borrás-Blasco J; Molés JR; Boscá M; Cortés E
PLoS One; 2015; 10(5):e0128156. PubMed ID: 26011514
[TBL] [Abstract][Full Text] [Related]
51. Safety of infliximab in children with IBD: the experience of an academic center in WV.
Northcutt M; Al-Subu A; Bella B; Elitsur Y
W V Med J; 2014; 110(3):26-9. PubMed ID: 24984403
[TBL] [Abstract][Full Text] [Related]
52. Home vs Hospital Infusion of Biologic Agents for Patients With Inflammatory Bowel Diseases.
Fenster M; Ungaro RC; Hirten R; Gallinger Z; Cohen L; Atreja A; Mehandru S; Colombel JF; Cohen BL
Clin Gastroenterol Hepatol; 2020 Jan; 18(1):257-258. PubMed ID: 30910602
[TBL] [Abstract][Full Text] [Related]
53. Individualized Infliximab Treatment Guided by Patient-managed eHealth in Children and Adolescents with Inflammatory Bowel Disease.
Carlsen K; Houen G; Jakobsen C; Kallemose T; Paerregaard A; Riis LB; Munkholm P; Wewer V
Inflamm Bowel Dis; 2017 Sep; 23(9):1473-1482. PubMed ID: 28617758
[TBL] [Abstract][Full Text] [Related]
54. A home infliximab infusion program.
Condino AA; Fidanza S; Hoffenberg EJ
J Pediatr Gastroenterol Nutr; 2005 Jan; 40(1):67-9. PubMed ID: 15625429
[TBL] [Abstract][Full Text] [Related]
55. Accelerated Infliximab Infusion Safety and Tolerability Is Non-inferior to Standard Infusion Protocol in Inflammatory Bowel Disease Patients: A Randomized Controlled Study.
Abushamma S; Walker T; Garza K; Chen L; Nix D; Chen CH
Crohns Colitis 360; 2023 Jul; 5(3):otad022. PubMed ID: 37288326
[TBL] [Abstract][Full Text] [Related]
56. Safety of Accelerated Infliximab Infusions in Children With Inflammatory Bowel Disease: A Retrospective Cohort Study.
Jagt JZ; Galestin SE; Claesen J; Benninga MA; de Boer NKH; de Meij TGJ
J Pediatr Gastroenterol Nutr; 2023 Sep; 77(3):373-380. PubMed ID: 37319101
[TBL] [Abstract][Full Text] [Related]
57. The safety of infliximab infusions in the community setting.
Ducharme J; Pelletier C; Zacharias R
Can J Gastroenterol; 2010 May; 24(5):307-11. PubMed ID: 20485705
[TBL] [Abstract][Full Text] [Related]
58. Short article: Remicade infusions at home: an alternative setting of infliximab therapy for patients with Crohn's disease.
Kuin S; Stolte SB; van den Brink GR; Ponsioen CY; Fockens P; D'Haens GR; Löwenberg M
Eur J Gastroenterol Hepatol; 2016 Feb; 28(2):222-5. PubMed ID: 26566062
[TBL] [Abstract][Full Text] [Related]
59. Efficacy and Safety of the Biosimilar Infliximab CT-P13 Treatment in Inflammatory Bowel Diseases: A Prospective, Multicentre, Nationwide Cohort.
Gecse KB; Lovász BD; Farkas K; Banai J; Bene L; Gasztonyi B; Golovics PA; Kristóf T; Lakatos L; Csontos ÁA; Juhász M; Nagy F; Palatka K; Papp M; Patai Á; Lakner L; Salamon Á; Szamosi T; Szepes Z; Tóth GT; Vincze Á; Szalay B; Molnár T; Lakatos PL
J Crohns Colitis; 2016 Feb; 10(2):133-40. PubMed ID: 26661272
[TBL] [Abstract][Full Text] [Related]
60. Antibodies to infliximab and risk of infusion reactions in patients with inflammatory bowel disease: a systematic review and meta-analysis.
O'Meara S; Nanda KS; Moss AC
Inflamm Bowel Dis; 2014 Jan; 20(1):1-6. PubMed ID: 24280879
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
